arrow
S

Shruti Sharma

natera, inc., austin, tx
H指数:21
被引数:4,070

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Molecular Residual Disease and Recurrence in Rectal Cancer Patients Undergoing Upfront Surgery: A Prospective Cohort Study

分子残留病灶及复发在行术前手术的直肠癌患者中的研究:一项前瞻性队列研究

2025-09-260
OAAI
ctDNA-based molecular residual disease and survival in resectable colorectal cancer

可切除结直肠癌中基于ctDNA的分子残留疾病和生存

2024-09-161
OAAI
Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial
2024-03-061
OAAI
Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma

IMvigor010 3期临床试验通过循环肿瘤DNA状态更新总生存期: 辅助阿特珠单抗与肌肉浸润性尿路上皮癌的观察比较

2024-02-0129
PRE
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial

新辅助阿特珠单抗联合化疗治疗胃和胃食管交界处腺癌: 2期熊猫试验

2024-01-0830
OAAI
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer

结直肠癌分子残留病变与辅助化疗疗效的研究

2023-01-16183
OAAI
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder
2022-08-0182
OA
Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences
2021-10-01127
OAAI
Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma
2019-07-015
PRE